Ali Athab Al-Kinani

Dr. Ali Athab Al-Kinani serves as Associate Professor in Clinical Pharmaceutics within the Department of Pharmacy at Kingston University's School of Life Sciences, Pharmacy and Chemistry. With over nine years of academic experience since his 2015 appointment, he holds significant university leadership roles including membership on the Board of Governors and Academic Council, and co-chairs the Institutional Athena Swan initiative.

His educational background includes:

• PhD in Therapeutics and Drug Delivery (Kingston University)
• MSc in Pharmaceutical Analysis with Distinction (Kingston University)
• BPharm (Baghdad College of Pharmacy)

Specializing in ocular drug delivery systems, his research pioneers 3D printing for personalized eye medicines, novel formulations for glaucoma and retinal diseases, and biological evaluation of drug delivery platforms. His work bridges pharmaceutical science with clinical applications, focusing on improving patient outcomes for chronic ocular conditions through innovative therapeutics.

His publication portfolio demonstrates consistent output in high-impact journals, with recent work emphasizing sustained-release systems, nanomicelle technologies, and antimicrobial eye formulations. This research trajectory reflects growing sophistication in material science applications for ophthalmic drug delivery.

Key recognitions include:

• AAPS Research Award in Analysis and Pharmaceutical Quality (2015)
• Kingston University Global Achiever Award (2015)
• GSK Best Poster Award (2011)
• Fellow of the Higher Education Academy (2016)

As an active grant holder with $685K in recent external funding from Qatar, he mentors eight doctoral students while leading curriculum development for Pharmacy programs. His leadership extends to national pedagogical innovation, notably developing Kingston's online examination framework during the pandemic which maintained accreditation standards while enhancing accessibility.

His laboratory group focuses on translating pharmaceutical innovations into clinical solutions, with two current projects generating patentable intellectual property for novel eye medicines.